Monitoring of therapy in atopic dermatitis--observations with the use of high-frequency ultrasonography

A Polańska1, W Silny, D Jenerowicz

  • 1Department of Dermatology and Venereology, University of Medical Sciences, Poznań, Poland.

Abstract

Insights

Tacrolimus therapy for atopic dermatitis can be effectively monitored using noninvasive high-frequency ultrasonography (HF-USG) and evaporimetry. These methods offer objective insights into skin changes, complementing traditional assessment scales.

Area of Science:

  • Dermatology
  • Medical Imaging
  • Pharmacology

Background:

  • Tacrolimus is a calcineurin inhibitor used in atopic dermatitis (AD) therapy.
  • Previous studies assessed tacrolimus efficacy using clinical scores.
  • Objective skin assessment methods were lacking in prior evaluations.

Purpose of the Study:

  • To evaluate tacrolimus therapy in AD patients over 6 months.
  • To monitor treatment effects using noninvasive techniques: high-frequency ultrasonography (HF-USG) and evaporimetry.
  • To compare objective measurements with clinical scores.

Main Methods:

  • 39 AD patients participated in the 6-month study.
  • Disease severity was assessed using Investigator's Global Assessment (IGA) score.
  • Noninvasive measurements included HF-USG (evaluating subepidermal low echogenic band - SLEB) and TEWL (transepidermal water loss) every 4 weeks.

Main Results:

  • Significant improvements were observed in IGA scores, SLEB, and TEWL during tacrolimus therapy.
  • Statistically significant differences in SLEB and TEWL were noted between lesional and nonlesional skin.
  • 54.6% of patients completed the 6-month study.

Conclusions:

  • High-frequency ultrasonography (HF-USG) is a useful, reproducible tool for monitoring tacrolimus therapy in atopic dermatitis.
  • HF-USG allows in vivo visualization of skin pathology, independent of subjective judgment.
  • HF-USG should be integrated into AD severity assessment alongside traditional scores for evidence-based medicine.